The drug was approved last year for patients with hypertension currently not controlled on other BP-lowering agents.

CCR5 antagonists show promise for stroke cerebroprotection and recovery, although further preclinical evidence in clinically relevant domains could strengthen support for clinical translation.

Amid a broader market selloff on Monday, Mizuho Securities upgraded the Cambridge, Massachusetts-based biotech Amylyx ...

US-based Apnimed has dosed the first subject in the multi-centre Phase IIA RESTEADY trial of SASS-001, an oral drug combo for ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First ...

Novartis (NVS) “announced the FDA has granted accelerated approval for Vanrafia, or atrasentan, a potent and selective endothelin A receptor ...

The farnesoid X receptor (FXR) is a bile acid nuclear receptor ... they identified DC646 as the most potent FXR antagonist, with an inhibition rate exceeding 70%. Molecular docking simulations ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to ...